Loading...
Ascletis Pharma Inc.
ASCLF•PNK
Healthcare
Biotechnology
$1.38
$0.00(0.00%)
Ascletis Pharma Inc. (ASCLF) Financial Performance & Income Statement Overview
Review Ascletis Pharma Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-97.73%
↓ 97.73%
Operating Income Growth
-31.48%
↓ 31.48%
Net Income Growth
-107.95%
↓ 107.95%
Operating Cash Flow Growth
100.00%
↑ 100.00%
Operating Margin
-5688.37%
↓ 5688.37%
Gross Margin
-125.17%
↓ 125.17%
Net Profit Margin
-3853.24%
↓ 3853.24%
ROE
-8.97%
↓ 8.97%
ROIC
-14.56%
↓ 14.56%
Ascletis Pharma Inc. (ASCLF) Income Statement & Financial Overview
Review Ascletis Pharma Inc.'s (ASCLF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $641500.00 | $641500.00 | $0.00 | $0.00 |
| Cost of Revenue | $274000.00 | $274000.00 | $0.00 | $0.00 |
| Gross Profit | $367500.00 | $367500.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.57 | $0.57 | $0.00 | $0.00 |
| R&D Expenses | $85.006M | $85.006M | $66.19M | $66.19M |
| SG&A Expenses | $30.19M | $30.19M | $20.68M | $20.68M |
| Operating Expenses | $115.20M | $115.20M | $86.87M | $86.87M |
| Total Costs & Expenses | $115.47M | $115.47M | $86.87M | $86.87M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.51M | $4.01M | $4.01M | $4.01M |
| EBITDA | -$111.83M | -$111.34M | -$82.96M | -$82.96M |
| EBITDA Ratio | -$174.33 | -$173.55 | ||
| Operating Income | -$114.83M | -$114.83M | -$86.87M | -$86.87M |
| Operating Income Ratio | -$179.006 | -$179.006 | ||
| Other Income/Expenses (Net) | $29.52M | $29.52M | $21.71M | $21.71M |
| Income Before Tax | -$85.31M | -$85.31M | -$65.16M | -$65.16M |
| Income Before Tax Ratio | -$132.98 | -$132.98 | ||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$99500.00 |
| Net Income | -$85.31M | -$85.31M | -$65.16M | -$65.16M |
| Net Income Ratio | -$132.98 | -$132.98 | ||
| EPS | -$0.09 | -$0.09 | -$0.06 | -$0.06 |
| Diluted EPS | -$0.09 | -$0.09 | -$0.06 | -$0.06 |
| Weighted Avg Shares Outstanding | $986.77M | $986.77M | $1.02B | $1.02B |
| Weighted Avg Shares Outstanding (Diluted) | $986.77M | $986.77M | $1.02B | $1.02B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan